These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Wallace JL Am J Med; 1999 Dec; 107(6A):11S-16S; discussion 16S-17S. PubMed ID: 10628589 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation. Colville-Nash PR; Gilroy DW Drug News Perspect; 2000 Dec; 13(10):587-97. PubMed ID: 12879130 [TBL] [Abstract][Full Text] [Related]
7. [Clinical application of cyclooxygenase-2 inhibitors]. Dzielska-Olczak M; Olczak S Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270 [TBL] [Abstract][Full Text] [Related]
8. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors. van der Bijl P; van der Bijl P Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Famaey JP Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063 [TBL] [Abstract][Full Text] [Related]
13. [Specific cyclooxygenase-2 inhibitors. Basis and options of a pharmacotherapeutic concept]. Hinz B; Brune K Anaesthesist; 2000 Nov; 49(11):964-71. PubMed ID: 11151817 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Jones MK; Wang H; Peskar BM; Levin E; Itani RM; Sarfeh IJ; Tarnawski AS Nat Med; 1999 Dec; 5(12):1418-23. PubMed ID: 10581086 [TBL] [Abstract][Full Text] [Related]
15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562 [TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. Chan FK Curr Pharm Des; 2003; 9(27):2213-9. PubMed ID: 14529402 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience with cyclooxygenase-2 inhibitors. van Ryn J; Pairet M Inflamm Res; 1999 May; 48(5):247-54. PubMed ID: 10391112 [TBL] [Abstract][Full Text] [Related]
19. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient]. Galli G; Panzetta G G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419 [TBL] [Abstract][Full Text] [Related]
20. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Noroian G; Clive D Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]